NEW YORK — For optic neuritis management, ophthalmologists must learn how to diagnose and treat antibody-mediated forms of the disease, according to a presenter.
“You need to know about two new kids on the block: antibody-mediated myelin oligodendrocyte glycoprotein (MOG) and neuromyelitis optica spectrum disorder (NMOSD), and the antibody is cell-based assay for aquaporin-4, or AQP4,” Lee told Healio at OSN New York Retina.
In a presentation, Andrew G. Lee, MD, said that despite the guidelines delivered in the Optic Neuritis Treatment Trial in 1992, ophthalmologists should perform gadolinium